NCT00257478
Completed
Phase 2
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Astellas Pharma Inc
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed prostate cancer.
- •Prior chemotherapy regimen for prostate cancer
Exclusion Criteria
- •History of other malignancy in the last 5 years
- •Major surgery within the past 21 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerProstate CancerNeoplasm MetastasisNCT00323882Bristol-Myers Squibb75
Terminated
Phase 2
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate CancerProstatic NeoplasmsNCT01545882Ottawa Hospital Research Institute5
Unknown
Not Applicable
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving ChemotherapyHormone Refractory Prostate CancerProstate CancerNCT00133900Immunicon276
Unknown
Phase 2
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate CancerProstate CancerNCT00657982Sheba Medical Center15
Completed
Not Applicable
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH AgonistsProstate CancerNCT01366053CMX Research125